Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

All products: general benefit

Other products in the same Health Canada class (N02A, N02AJ) — coverage varies; not interchangeable

  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit
  • Acetylsalicylic acid + oxycodone (Ratio-Oxycodan): general benefit, Not a benefit
  • Acetaminophen + tramadol (Tramacet): not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit

4 more in the class list below

Teva-Lenoltec No.3 · DIN 00653276 · 300mg & 15mg & 30mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Lenoltec No.3 · DIN 00653276 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2018-10-19 · brand TEVA-LENOLTEC NO. 3 · ATC N02AJ06 CODEINE AND PARACETAMOL, N02AJ06 CODEINE AND PARACETAMOL · form Tablet · route Oral · ingredients CAFFEINE 15 MG, ACETAMINOPHEN 300 MG, CODEINE PHOSPHATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Lenoltec No.3: Formulary list price $0.0980/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0980 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6346 · Verify on the e-Formulary ↗ (DIN 00653276)

Source record
DIN 00653276: Teva-Lenoltec No.3 Raw flags: sec3=Y Item: 280808005; group id 396; item number 0948; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg & 15mg & 30mg Recorded listing: General benefit Source prices (unrounded): $0.0980; ministry $0.0980 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00653276 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6346
Interchangeable products
Tylenol with Codeine No. 3 · DIN 02163926 · not recorded
Shortage status: resolved shortage (ended 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00653276
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy. Pediatrics (< 18 years of age) There are limited safety and efficacy studies with acetaminophen and codeine in the pediatric population. Therefore, the use of TEVA-LENOLTEC No. 2 and No. 3 are not recommended in patients over 12 and under 18 years of age. Regardless of clinical setting, the use of codeine, including TEVA-LENOLTEC No. 2 and No. 3, is contraindicated in patients below the age of 12 years due to increased safety concerns (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). https://pdf.hres.ca/dpd_pm/00065848.PDF PM date: July 15, 2014 Source product: TEVA-LENOLTEC NO. 2; DIN 00653241; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.